Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07212101 · ClinicalTrials.gov registry record · NA
Sleep in Collegiate Baseball Players
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT07212101: Completed NA study, sponsored by Columbia University.
NCT07212101 is a NA study that has completed, run by Columbia University. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07212101, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
Sleep is an essential biological function that impacts nearly every aspect of an athlete's physical and mental health. For athletes, the importance of high-quality sleep cannot be overstated, as it plays a critical role in performance, recovery, and overall well-being. Sleep supports muscle recovery by promoting protein synthesis and the release of growth hormones, essential for healing after intense physical exertion. Furthermore, adequate sleep is crucial for maintaining cognitive sharpness, decision-making abilities, and emotional regulation-all of which are necessary for optimal athletic performance. The study will assess both sleep quality and quantity in baseball players at Columbia University. These tools will help quantify key sleep metrics, including sleep duration, latency (the time it takes to fall asleep), and the number of awakenings during the night. Similarly, the study will analyze dietary patterns using the Automated Self-Administered 24-Hour Dietary Assessment (ASA24), tracking nutrient intake, meal timing, and the consumption of ultra-processed foods. These assessments will establish a baseline from which to measure improvement post-intervention. The intervention will focus on improving diet, time in bed, and light exposure to improve sleep, diet, and performance in collegiate baseball athletes.
Primary Outcome
Batters: Baseball radar gun, outcome is exit velocity (speed at which ball leaves the bat, in miles/h) Pitchers: Baseball radar gun measuring velocity (miles/h)
Interventions
- BEHAVIORAL Sleep and diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2025-10-31 |
| Phase | NA |
What the finished NCT07212101 record still lists
NCT07212101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Sleep and diet is the first listed.
NCT07212101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07212101 about?
NCT07212101 is a clinical study titled "Sleep in Collegiate Baseball Players". Sleep is an essential biological function that impacts nearly every aspect of an athlete's physical and mental health. For athletes, the importance of high-quality sleep cannot be overstated, as it plays a critical role in performance, recovery, and overall well-being. Sleep supports muscle recovery...
What is the current status of trial NCT07212101?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2025-09-16. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT07212101?
The interventions under investigation include: Sleep and diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT07212101?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07212101's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI